SLG
CPRX

Stanley-Laman Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Stanley-Laman Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.84M Buy
155,021
+15,629
+11% +$372K 0.47% 81
2025
Q4 		$3.25M Sell
139,392
-3,292
-2% -$73.3K 0.41% 94
2025
Q3 		$2.81M Sell
142,684
-1,335
-0.9% -$27.5K 0.4% 98
2025
Q2 		$3.13M Sell
144,019
-409
-0.3% -$9.65K 0.46% 98
2025
Q1 		$3.5M Buy
+144,428
New +$3.25M 0.54% 81

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Stanley-Laman Group's CPRX Position: Q1 2026 in Review

Stanley-Laman Group increased its Catalyst Pharmaceutical (CPRX) stake by 11% in Q1 2026, buying an estimated $372K and bringing the position to 155,021 shares worth $3.84M. The position accounts for 0.47% of the portfolio, ranked #81.

Stanley-Laman Group first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Stanley-Laman Group held 155,021 shares of Catalyst Pharmaceutical worth $3.84M as of Q1 2026.
  • Stanley-Laman Group bought 15,629 Catalyst Pharmaceutical shares in Q1 2026, an estimated $372K.
  • Catalyst Pharmaceutical made up 0.47% of Stanley-Laman Group's portfolio in Q1 2026, its #81 holding.
  • Stanley-Laman Group first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Stanley-Laman Group's 13F filing for Q1 2026, filed 16 Apr 2026.